Page 18 - Contracts And Orders News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Contracts and orders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Contracts And Orders Today - Breaking & Trending Today

CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration

Press release content from Business Wire. The AP news staff was not involved in its creation.
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration
February 25, 2021 GMT
BEIJING & CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 25, 2021
CANbridge Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing drug candidates in China and North Asia, and Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, have agreed to terminate their 2018 license agreement, in which Puma granted CANbridge exclusive rights to develop and commercialize NERLYNX® (neratinib) in Greater China, and to settle their arbitration related to the license agreement. ....

United States , Hong Kong , Pierre Fabre , James Xue , Puma Biotechnology Inc , Umass Medical School , Horae Gene Therapy Center , Canbridge Pharmaceuticals Inc , Planet Communications , North Asia , Puma Biotechnology , Greater China , Middle East , Positive Breast , Wuxi Biologics , Medical School , Pharmaceuticals Inc , Fetal Toxicity , Full Prescribing Information , Puma Patient Lynx , Business Wire , Products And Services , Diagnosis And Treatment , Licensing Agreements , Pharmaceutical Manufacturing , Health Care Industry ,

Global $71.43 Billion Telepharmacy Market to 2027 - ResearchAndMarkets.com

Press release content from Business Wire. The AP news staff was not involved in its creation.
Global $71.43 Billion Telepharmacy Market to 2027 - ResearchAndMarkets.com
February 25, 2021 GMT
DUBLIN (BUSINESS WIRE) Feb 25, 2021
ADVERTISEMENT
Telepharmacy refers to the process of delivering the pharmaceutical care through telecommunications to the patients across various locations where getting consultation from any healthcare professional is next to impossible. Telepharmacy is a subset of telemedicine which is a wider term used by the healthcare experts.
Certain services involved in telepharmacy includes patient counselling, drug therapy monitoring, refill authorization and prior authorization needed for the prescription drugs. Other telepharmacy services comprises of monitoring the formulary compliance through the deployment of videoconferencing or teleconferencing. ....

United States , Laura Wood , Telepharmacy Solutions , Medtel Services , Mitsui Co , Office Hours Call , Research Methodology , Youscript Incorporated , Pipeline Health Holdings , Company Profiles , Mitsui Co Inc , E St Office Hours Call , Pharmacy Services Inc , Medication Review Inc , Telepharmacy Solutions Inc , Market Share , Industry Analysis Report , End Use , Segment Forecast , Medication Review , North West Telepharmacy Solutions , Mckesson Ventures , One Touch Telehealth , Comprehensive Pharmacy Services , Topics Covered , Market Assessment ,

SOS Kicks off Constructions of Cloud Crypto Mining Center in Hejiang County, Luzhou, Sichuan

Press release content from PR Newswire. The AP news staff was not involved in its creation. ....

Yandai Wang , Information Technology Co Ltd , Leibodong Cloud Crypto Mining Center , Leibodong Hydropower Station , Zhejiang County , News Today , E Commerce Today , Private Securities Litigation Reform Act , Annual Report , Products And Services , Block Chain , Coronavirus Pandemic , Cloud Computing Services , Artificial Intelligence , Financial Technology , Cloud Computing , Greater China , Pr Newswire , Search And Rescue Efforts , Lung Disease , Covid 19 Pandemic , East Asia , Software Industry , Computer And Data Security , Infectious Diseases , Contracts And Orders ,

Fluor Reports Fourth Quarter and Full Year 2020 Results

Press release content from Business Wire. The AP news staff was not involved in its creation.
Fluor Reports Fourth Quarter and Full Year 2020 Results
February 26, 2021 GMT
IRVING, Texas (BUSINESS WIRE) Feb 26, 2021
Fluor Corporation (NYSE: FLR) today announced financial results for its year ended December 31, 2020. Results for 2020 were a net loss from continuing operations attributable to Fluor of $294 million, or $2.09 per diluted share, compared to a net loss from continuing operations attributable to Fluor of $1.5 billion, or $10.89 per diluted share in 2019. Consolidated segment profit for the year was $317 million compared to a loss of $186 million in 2019. Consolidated continuing operations for the year included non-cash impairments and charges of approximately $358 million to reflect the impact of weak commodity prices and COVID-19. Operating cash flow in 2020 was $186 million compared to $219 million in 2019. ....

United States , Jason Landkamer , Brian Mershon , Fluor Investor Relations Department , Fluor Corporation , Company Form , Exchange Commission , Energy Chemicals , David Constable , South America , Diversified Services , Looking Statements , Investor Relations Department , Cont Ops , Business Wire , Government Business And Finance , Government Contracts , North America , Covid 19 Pandemic , Corporate News , Coronavirus Pandemic , Financial Performance , Lung Disease , Diseases And Conditions , Government And Politics , Infectious Diseases ,

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent .
SpringWorks Therapeutics, Inc.February 25, 2021 GMT
- Reported Interim Data from Phase 2b ReNeu Trial of Mirdametinib in NF1-PN Demonstrating Encouraging Clinical Activity and Tolerability in the First 20 Adult Patients Enrolled -
-
- Continued to Strengthen Nirogacestat Patent Portfolio -
- Multiple Data Readouts Expected in 2021 Across
Pipeline, Including Topline Data from Phase 3 DeFi Trial in Desmoid Tumors and Initial Nirogacestat BCMA Combination Data -
ADVERTISEMENT
- Ended 2020 with $561.8 Million in Cash, Cash Equivalents and Marketable Securities - ....

United States , Southwest Finland , Saqib Islam , Tatu Pantsar , Children Oncology Group , Jazz Pharmaceuticals , Drug Administration , University Of Eastern Finland , Exchange Commission , Development Rd Expenses , Trademark Office For Patent Application No , Springworks Therapeutics Inc , Interim Data , Reneu Trial , Encouraging Clinical Activity , Patients Enrolled , Janssen Sponsored Phase , Evaluating Nirogacestat , Have Initiated , Strengthen Nirogacestat Patent Portfolio , Data Readouts Expected , Including Topline Data , Desmoid Tumors , Initial Nirogacestat , Cash Equivalents , Marketable Securities ,